What Does the Published Research Say About CJC-1295 Without DAC?

What This Article Covers

This article summarizes published research on CJC-1295 Without DAC for technical review. It separates direct human evidence, review-level context, and animal or mechanistic work so the reader can see what has actually been tested before seeing the limitations.

This synthesis isolates what the included literature shows—and does not show—about CJC-1295 without DAC. The evidence set contains: two human study sources (a pharmacodynamic study in healthy adults and a human biomarker study; plus a clinical trial registry entry in a disease-specific context), plus three preclinical/analytical sources. Importantly, the direct human data provided (e.g., [pubmed:16352683], [pubmed:19386527]) describe a long-acting CJC-1295 GHRH analog; these should not be treated as interchangeable with a non-DAC variant.

Bottom Line

Published research in this evidence set shows that a long-acting CJC-1295 GHRH analog can prolong GH and IGF-1 secretion in healthy adults and alter serum protein profiles (biomarker-level findings) [pubmed:16352683][pubmed:19386527]. A clinical trial was registered to evaluate CJC-1295 in HIV-associated visceral obesity, but no peer-reviewed outcomes are provided here [clinicaltrials:NCT00267527]. Analytical studies in equine matrices describe detection methods, not therapeutic effects [pubmed:30938069][pubmed:30489688]. These sources do not establish clinical outcomes for a non-DAC CJC-1295 variant.

—

What Was Tested in Humans?

• Pharmacodynamic study (healthy adults): A long-acting CJC-1295 GHRH analog produced prolonged stimulation of GH and IGF-1 secretion. Context noted that native GHRH has short duration, motivating evaluation of longer-acting analogs [pubmed:16352683].
• Human biomarker/mechanistic study (normal adults): Activation of the GH/IGF-1 axis by CJC-1295 (long-acting GHRH analog) was associated with changes in serum protein profiles. This is biomarker-level/mechanistic evidence and not controlled clinical outcome data [pubmed:19386527].
• Disease-specific clinical trial registry entry: A study was registered to evaluate CJC-1295 in HIV patients with visceral obesity; the evidence set does not provide peer-reviewed outcomes from this trial [clinicaltrials:NCT00267527].

Variant alignment clarification: The human studies above pertain to a long-acting CJC-1295 formulation. Given this article’s focus on “CJC-1295 without DAC,” these data should not be used as stand-in evidence for a non-DAC variant.

—

What Did Animal and Mechanistic Studies Show?

The available evidence set should be interpreted carefully when it includes animal, cellular, formulation, or mechanistic findings. Those findings can explain why researchers study the compound, but they should not be presented as established human outcomes.

How the Evidence Fits Together

The practical reading for CJC-1295 Without DAC is evidence hierarchy. Human studies, when present, carry the most weight, but only for the exact population, route, comparator, and endpoint studied. Reviews can help map the field, and animal or mechanistic studies can explain biological plausibility, but neither should be used to leap beyond the human evidence.

What Is Not Established

• No direct human outcome data specific to a non-DAC CJC-1295 variant are included in this evidence set.
• Dosing and general safety across off-label or non-study populations are not addressed here.
• Biomarker changes (GH/IGF-1, serum protein profiles) do not establish clinical benefit [pubmed:16352683][pubmed:19386527].
• Extrapolation from a disease-specific registry entry (HIV-associated visceral obesity) to broader populations or indications is not supported without published outcomes [clinicaltrials:NCT00267527].
• Analytical method papers in equine models are not evidence of therapeutic effects [pubmed:30938069][pubmed:30489688].

—

Research-Use Boundary

This article summarizes published research and regulatory-source discussion for technical review. It is not medical advice, not a dosing guide, and not a recommendation for human or veterinary use. KRL materials are sold for research use only and are not for diagnostic, therapeutic, or administration purposes.

Selected Sources

• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. https://pubmed.ncbi.nlm.nih.gov/16352683/ [pubmed:16352683]
• A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS. https://pubmed.ncbi.nlm.nih.gov/30938069/ [pubmed:30938069]
• An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. https://pubmed.ncbi.nlm.nih.gov/30489688/ [pubmed:30489688]
• Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. https://pubmed.ncbi.nlm.nih.gov/19386527/ [pubmed:19386527]
• A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. https://clinicaltrials.gov/study/NCT00267527 [clinicaltrials:NCT00267527]
• PubChem compound record: CJC 1295. https://pubchem.ncbi.nlm.nih.gov/compound/91971820 [pubchem:91971820]
• Google Patents search for CJC-1295. https://patents.google.com/?q=CJC-1295 [patent_search:cjc-1295]

Related KRL Resources

• Research Compound Catalog
• Technical Products
• FAQ